• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Hausman Diana bought $19,862 worth of shares (5,500 units at $3.61) (SEC Form 4)

    7/7/25 8:59:25 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMRX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    HAUSMAN DIANA

    (Last) (First) (Middle)
    245 MAIN STREET
    2ND FLOOR

    (Street)
    CAMBRIDGE MA 02142

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Immuneering Corp [ IMRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 07/02/2025 P 2,500 A $3.5956 2,500 D
    Class A Common Stock 07/02/2025 P 3,000 A $3.6245 3,000 I By spouse
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    /s/ Michael D. Bookman, Attorney-in-Fact for Diana F. Hausman 07/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IMRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMRX

    DatePrice TargetRatingAnalyst
    12/13/2024Equal-Weight → Underweight
    Morgan Stanley
    3/15/2024$20.00 → $15.00Buy
    Needham
    3/15/2024Outperform → Market Perform
    TD Cowen
    3/15/2024$16.00 → $3.00Buy → Hold
    Jefferies
    12/1/2023$20.00Buy
    Needham
    6/26/2023$25.00Outperform
    Oppenheimer
    4/19/2023$5.00 → $14.00Underweight → Equal-Weight
    Morgan Stanley
    4/19/2023$10.00 → $20.00Neutral → Buy
    Mizuho
    More analyst ratings

    $IMRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

    NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. "These exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed durin

    9/26/25 4:01:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

    NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public offering of 18,959,914 shares of its Class A common stock at an offering price of $9.23 per share, which is equal to the last reported sale price for Immuneering's Class A common stock on The Nasdaq Global Market on September 24, 2025. In addition, Immuneering has granted the underwriters a 30-day option to purchase up to an additional 2,843,987 shares of Class A common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from t

    9/25/25 12:08:31 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

    NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of shares of its Class A common stock or, in lieu of Class A common stock, pre-funded warrants to purchase Class A common stock (the "Offering"). In addition, Immuneering intends to grant the underwriters a 30-day option to purchase up to a number of additional shares of Class A common stock equal to fifteen percent (15%) of the shares of Class A common stock and pre-funded warrants initially offered in the Offering. Immuneering also announced that Sanofi has entered into a sec

    9/24/25 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Feinberg Peter bought $35,900 worth of shares (5,000 units at $7.18), increasing direct ownership by 4% to 141,766 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    9/30/25 9:00:58 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF PEOPLE OFFICER Neufeld Leah R was granted 11,815 shares, increasing direct ownership by 110% to 22,544 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    9/17/25 4:41:20 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Morales Mallory was granted 14,497 shares, increasing direct ownership by 114% to 27,233 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    9/17/25 4:35:58 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Feinberg Peter bought $35,900 worth of shares (5,000 units at $7.18), increasing direct ownership by 4% to 141,766 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    9/30/25 9:00:58 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hausman Diana bought $19,862 worth of shares (5,500 units at $3.61) (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    7/7/25 8:59:25 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF PEOPLE OFFICER Neufeld Leah R bought $2,499 worth of shares (700 units at $3.57), increasing direct ownership by 7% to 10,729 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    7/7/25 8:52:03 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Immuneering Corporation downgraded by Morgan Stanley

    Morgan Stanley downgraded Immuneering Corporation from Equal-Weight to Underweight

    12/13/24 8:04:38 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on Immuneering Corporation with a new price target

    Needham reiterated coverage of Immuneering Corporation with a rating of Buy and set a new price target of $15.00 from $20.00 previously

    3/15/24 7:50:35 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation downgraded by TD Cowen

    TD Cowen downgraded Immuneering Corporation from Outperform to Market Perform

    3/15/24 7:19:50 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    SEC Filings

    View All

    SEC Form 424B5 filed by Immuneering Corporation

    424B5 - Immuneering Corp (0001790340) (Filer)

    9/25/25 5:26:30 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Immuneering Corp (0001790340) (Filer)

    9/25/25 5:23:28 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Immuneering Corporation

    FWP - Immuneering Corp (0001790340) (Subject)

    9/25/25 6:01:41 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Leadership Updates

    Live Leadership Updates

    View All

    Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos®, a first-in-class oral therapy for ANCA-associated vasculitis. Under his leadership, ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion. His career

    9/16/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

    - Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - First Patient Dosed in Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations; Initial PK, PD and safety data expected in 2024 - CAMBRIDGE

    5/7/24 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

    CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors. "On behalf of the entire Immuneering team, we are honored to welcome Dr. Schall to our Board," said Ben Zeskind, Chief Executive Officer, Immuneering Corporation. "Tom's extensive experience developing new medicines, including 25 years guiding drug discovery, development and commercialization

    3/12/24 8:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Financials

    Live finance-specific insights

    View All

    Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

    NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. "These exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed durin

    9/26/25 4:01:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

    - 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal trial plans in Q4 2025 and, subject to that feedback, expects to initiate pivotal trial by the end of 2025 and begin dosing patients by mid-2026 - NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced positive updated survival and safety data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified gemcita

    9/24/25 4:01:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

    - Company plans to host an investor call at 8 a.m. ET on September 25 - - Immuneering plans to then share the updated data at the PanCAN Scientific Summit on September 28 - - Additionally, the Company will present a review of preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit - CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today shared plans to announce updated overall survival data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up on Thursday, September 25, 2025. Th

    9/10/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    11/14/24 4:15:35 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    11/14/24 3:03:47 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    4/15/24 6:10:57 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care